Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

26 patients presenting a rhegmatogenous retinal detachment with more than 4 days of duration will be prospectively included.

A single dose of ursodeoxycholic acid will be administered orally before surgery at different time-points in 22 subjects. Standard surgery will be performed and ocular samples will be collected during the procedure. Ursodeoxycholic acid treatment will be continued in treated patients during 3 months after surgery.

Ocular and serum samples from the 4 untreated patients will serve as negative controls for the determination of UDCA levels.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Francine Behar-Cohen
• Collaborators: Emory University; University of Lausanne Hospitals
• Treatments: Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

• Patients presenting a rhegmatogenous retinal detachment with more than 4 days from symptoms onset.

Exclusion Criteria:

• Previous vitrectomy, vitreous bleeding, other associated retinal disease.

• Monophthalmic patients.

• Pregnancy and lactation, peptic ulcer, acute or chronic liver disease, acute infection of the gallbladder and biliary tract, repeated biliary colic, Crohn's disease, ulcerative colitis, or other disease of the small intestine and colon, and hypersensitivity.

• Patients treated by Cholestyramine, Colestipol and Antacids containing aluminum hydroxide or magnesium, Cyclosporine, Ciprofloxacin, Nitrendipine, Dapsone.

• Patients presenting with galactose intolerance, the Lapp lactase deficiency or glucose and galactose malabsorption.